RU2020129820A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2020129820A3 RU2020129820A3 RU2020129820A RU2020129820A RU2020129820A3 RU 2020129820 A3 RU2020129820 A3 RU 2020129820A3 RU 2020129820 A RU2020129820 A RU 2020129820A RU 2020129820 A RU2020129820 A RU 2020129820A RU 2020129820 A3 RU2020129820 A3 RU 2020129820A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810144817.4A CN110144008B (zh) | 2018-02-12 | 2018-02-12 | Cd38蛋白抗体及其应用 |
| CN201810144817.4 | 2018-02-12 | ||
| PCT/CN2019/074806 WO2019154421A1 (zh) | 2018-02-12 | 2019-02-11 | Cd38蛋白抗体及其应用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2020129820A RU2020129820A (ru) | 2022-03-14 |
| RU2020129820A3 true RU2020129820A3 (cg-RX-API-DMAC7.html) | 2022-03-14 |
| RU2776795C2 RU2776795C2 (ru) | 2022-07-26 |
Family
ID=
Also Published As
| Publication number | Publication date |
|---|---|
| KR102770962B1 (ko) | 2025-02-24 |
| US11713357B2 (en) | 2023-08-01 |
| WO2019154421A1 (zh) | 2019-08-15 |
| JP2021512652A (ja) | 2021-05-20 |
| RU2020129820A (ru) | 2022-03-14 |
| KR20200120937A (ko) | 2020-10-22 |
| BR112020016271A2 (pt) | 2020-12-15 |
| JP7333523B2 (ja) | 2023-08-25 |
| SG11202007443XA (en) | 2020-09-29 |
| US20210024645A1 (en) | 2021-01-28 |
| AU2019218518B2 (en) | 2025-07-10 |
| CN114835809A (zh) | 2022-08-02 |
| EP3753955A1 (en) | 2020-12-23 |
| CN111712521B (zh) | 2022-03-15 |
| EP3753955A4 (en) | 2021-12-08 |
| AU2019218518A1 (en) | 2020-10-01 |
| CA3091492A1 (en) | 2019-08-15 |
| TWI818952B (zh) | 2023-10-21 |
| CA3091492C (en) | 2023-10-10 |
| CN111712521A (zh) | 2020-09-25 |
| CN110144008B (zh) | 2021-03-19 |
| TW201934577A (zh) | 2019-09-01 |
| CN110144008A (zh) | 2019-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021000792B8 (cg-RX-API-DMAC7.html) | ||
| AT524834A2 (cg-RX-API-DMAC7.html) | ||
| AU2018438767B1 (cg-RX-API-DMAC7.html) | ||
| AT521543A3 (cg-RX-API-DMAC7.html) | ||
| AT524266A2 (cg-RX-API-DMAC7.html) | ||
| BR102019026286B1 (pt) | Método e aparelho para o avanço de produtos a serem moldados | |
| BR102019025884B1 (pt) | Sistema de segurança aprimorado para máquinas de operação de autopropulsão | |
| BR102019023514B1 (pt) | Método para determinar a massa de ar preso em cada cilindro de um motor a combustão interna | |
| BR112021001434B1 (pt) | Aço com alto teor de manganês e método de produção do mesmo | |
| BR112021001374B1 (pt) | Composição farmacêutica para o tratamento da hipertensão e seu uso | |
| BR112021001128B1 (pt) | Composição de cimento para impressão 3d, método de impressão 3d, kit para a preparação de uma composição de cimento para impressão 3d e método de impressão 3d implementando o kit | |
| BR112021001186B1 (pt) | Aparelho para o tratamento de celulite para tratar expressões de celulite na pele de um paciente associadas a um local de tratamento de septos | |
| BR112020023795B1 (pt) | Composição de recheio para um produto de chocolate à base de gordura, e seus métodos de produção | |
| BR112021000922B1 (pt) | Tela de filtro, e, método para purificar água de alimentação | |
| BR112020026077B1 (pt) | Recipiente com estrutura encaixável | |
| BR112020023832B1 (pt) | Amostra de calibração de sistemas de análise multiespectral e método para calibração de sistemas de análise multiespectral | |
| BR112020024987B1 (pt) | Método, montagem e sistema para prover uma estrutura de base, método industrial, e, braço mecânico | |
| BR112020023823B1 (pt) | Distribuidor | |
| BR112020022482B1 (pt) | Composição, anticorpo anti-cd24, anticorpo biespecífico e receptor de antígeno quimérico | |
| BR112020022658B1 (pt) | Método para estimar um nível de pressão sonora, sistema de fone de ouvido, fone de ouvido e uso do fone de ouvido | |
| BR112020021042B1 (pt) | Compostos de carboxamidas bicíclicas, composição farmacêutica e uso das mesmas | |
| BR112020020812B1 (pt) | Composições de tratamento de superfícies duras, seu uso, método para proporcionar ação antimicrobiana residual e substrato relacionado | |
| BR112020015757B1 (pt) | Métodos, sistema, kit e dispositivos para visualização e remoção de tumor | |
| BR102019000241B1 (pt) | Veículo modular, configurável, sobre plataforma de chassis comum, e métodos e sistemas associados | |
| BR102018073077B1 (pt) | Processo de extração de gelatina de resíduos de couro curtido ao cromo wet blue |